PACUPod is your trusted source for evidence-based insights tailored to advanced clinical pharmacists and physicians. Each episode dives into the latest primary literature, covering medication-focused studies across specialty pharmacy, and many more. We break down study designs, highlight key findings, and objectively discuss clinical implications—without the hype—so you stay informed and ready to apply new evidence in practice. Whether you’re preparing for board certification or striving for excellence in patient care, PACUPod helps you make sense of the data, one study at a time.
Britany: Welcome back to PACULit, your go-to source for clinical literature updates. Today, we’re discussing the four-year safety and efficacy data of deucravacitinib in moderate to severe plaque psoriasis from Armstrong and colleagues’ 2025 integrated analysis. Seth, great to have you here.
Seth: Thanks, Britany. Plaque psoriasis affects 2 to 3 percent globally, with moderate to severe cases impacting quality of life and increasing risks for psoriatic arthritis and cardiovascular disease. Despite many treatments, long-term safety and sustained efficacy remain key concerns.
Britany: Exactly. This study fills a gap. Earlier POETYK PSO-1 and PSO-2 trials showed deucravacitinib’s superiority over placebo and apremilast short-term, but data beyond one year were lacking. This four-year extension clarifies durability and safety over time.
Seth: Mechanistically, deucravacitinib is a selective oral TYK2 inhibitor targeting IL-12, IL-23, and type I interferons—key cytokines in psoriasis. This selectivity may offer a better safety profile than broader JAK inhibitors, important for chronic use.
Britany: That’s crucial. Patients uncontrolled or intolerant to topical or systemic therapies often want oral options with good long-term tolerability. Deucravacitinib fits that niche.
Seth: The study combined two Phase 3 randomized controlled trials—POETYK PSO-1 and PSO-2—and a long-term extension (LTE). The parent trials were double-blind with placebo and apremilast controls.
Britany: The LTE was open-label, enrolling patients who completed the parent trials, allowing up to four years of deucravacitinib exposure. Inclusion criteria: adults 18+, moderate to severe plaque psoriasis defined by PASI ≥12, body surface area ≥10%, and PGA ≥3.
Seth: They excluded non-plaque psoriasis, recent biologic use, and uncontrolled comorbidities to create a homogenous population for long-term assessment.
Britany: Intervention was deucravacitinib 6 mg orally once daily. Parent trials had placebo and apremilast 30 mg twice daily comparators. LTE was open-label deucravacitinib 6 mg daily for all.
Seth: Primary efficacy endpoints were PASI 75, 90, and 100 responses, plus PGA 0 or 1. Secondary endpoints included Dermatology Life Quality Index (DLQI) 0 or 1, indicating minimal impact. Safety endpoints covered adverse events, serious adverse events, major cardiovascular events, malignancies, venous thromboembolism, and deaths.
Britany: Parent trials lasted 16 to 52 weeks; LTE extended to four years. Safety used exposure-adjusted incidence rates per 100 patient-years, accounting for varying exposure durations.
Seth: Key findings: over four years, adverse event rates decreased from 229.23 to 131.68 per 100 patient-years, suggesting improved tolerability or fewer new events over time.
Britany: Serious adverse events dropped slightly from 5.68 to 5.01, and discontinuations due to adverse events fell from 4.38 to 2.20 per 100 patient-years, indicating patients generally stayed on therapy without major safety issues.
Seth: Herpes zoster incidence decreased from 0.81 to 0.55 per 100 patient-years, reassuring given immunomodulation. Malignancies and venous thromboembolism rates were low and stable or declining—malignancies from 1.02 to 0.89, VTE from 0.20 to 0.07.
Britany: Major adverse cardiovascular events remained stable around 0.30 to 0.32, and deaths were rare, 0.20 at one year and 0.25 at four years. Overall, safety was consistent and manageable.
Seth: Efficacy: among ~513 continuously treated patients, PASI 90 response was 45.6% at one year and 47.5% at four years—impressive durability.
Britany: DLQI 0/1 rates were steady, about 51.5% at one year and 49.4% at four years, showing sustained quality of life improvements aligned with clinical efficacy.
Seth: Clinically, monitoring for infections like herpes zoster early in treatment is important. The decreasing incidence suggests immune adaptation or front-loaded risk.
Britany: Also, deucravacitinib’s selective TYK2 inhibition may avoid hematologic and lipid abnormalities seen with broader JAK inhibitors, a meaningful clinical advantage.
Seth: Regarding drug interactions, deucravacitinib is metabolized mainly via CYP1A2 and CYP2B6. Strong inducers or inhibitors of these enzymes can affect levels. For example, smoking induces CYP1A2 and may reduce efficacy.
Britany: Patients with significant hepatic impairment were excluded, so caution is needed there. Real-world data will help characterize safety in elderly or comorbid populations.
Seth: The trials excluded recent biologic users and uncontrolled comorbidities, so while data are robust, caution is needed when applying results to complex patients.
Britany: Still, with over 1500 patients and long follow-up, the findings are generalizable. Combining randomized and extension phases strengthens the evidence.
Seth: Limitations include the open-label LTE design, which may introduce bias, especially in subjective endpoints like quality of life. Attrition bias is possible since efficacy analyses focused on continuous treatment completers.
Britany: Also, lack of active comparator beyond 52 weeks limits long-term comparative efficacy insights. But consistent safety and efficacy signals are encouraging.
Seth: Clinically, deucravacitinib offers a convenient oral option with durable efficacy and manageable safety for moderate to severe plaque psoriasis. Providers should emphasize adherence, monitor infections, and counsel on adverse event recognition.
Britany: Coordinating lab assessments per guidelines is key, especially monitoring hematologic or hepatic changes, though these were uncommon in trials.
Seth: Overall, this four-year data supports deucravacitinib as a valuable addition to psoriasis treatment, especially for patients seeking oral systemic therapy with sustained benefit.
Britany: To summarize, Armstrong et al. provide compelling evidence that deucravacitinib maintains PASI 90 responses and quality of life improvements over four years with a consistent, manageable safety profile. This long-term data fills a critical gap and guides chronic management.
Seth: Absolutely. Durable efficacy paired with reassuring safety is exciting in a chronic inflammatory disease requiring long-term treatment.
Britany: Thanks for the discussion, Seth. And thanks to our listeners for tuning in to PACULit. Check out the full study in the *Journal of the European Academy of Dermatology and Venereology* for details.
Seth: Thanks, everyone. Stay curious and keep up with the latest evidence to optimize patient care.
Britany: Until next time!